Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation

Add time:08/08/2019    Source:sciencedirect.com

Autotaxin (ATX) is a potential target for the treatment of various cancers. A new series of ATX inhibitors was rationally designed and synthesized based on our previous study. Biological evaluation and structure-activity relationship (SAR) of this series are discussed. Among fourteen synthesized derivatives, six compounds (2, 3, 4, 12, 13 and 14) exhibited enhanced ATX inhibitory activities with IC50 values in the low nanomolar range. Molecular interactions of all the synthesized compounds within the active site of ATX were studied through molecular docking studies. Herein, we describe our lead optimization efforts that resulted in the identification of a potent ATX inhibitor (compound 4 with IC50 = 1.23 nM, FS-3 and 2.18 nM, bis-pNPP). Furthermore, pharmacokinetic properties of this most promising compound are profiled.

We also recommend Trading Suppliers and Manufacturers of ATX 70 (cas 135099-39-7). Pls Click Website Link as below: cas 135099-39-7 suppliers

Prev:Suppressiveness of white vinegar and steam-exploded liquid waste against the causal agents of Pleurotus eryngii yellowing
Next:Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis)